Replies to post #171550 on Biotech Values

[oc631]

They had no choice; if GILD hadn’t tested an 8-week regimen in at least one phase-3 trial, the backlash from patient advocacy groups and third-party payers would’ve been severe and likely caused economic harm.

Just because it's a 8-week regimen doesn't guarantee advocacy groups will be happy with the price.

[ciotera]

Re: 8 vs. 12 week

The interesting thing is that if what you say is true and they go with 12 week as far as pricing and what's in the label, a lot of people will use it for 8, so knowing this they will need to go in with a higher price which opens the door wider for price competition from ABBV and mix-and-match regimens.